RT Journal Article
SR Electronic
T1 Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.03.23284131
DO 10.1101/2023.01.03.23284131
A1 Hogan, Alexandra B
A1 Doohan, Patrick
A1 Wu, Sean L
A1 Mesa, Daniela Olivera
A1 Toor, Jaspreet
A1 Watson, Oliver J
A1 Winskill, Peter
A1 Charles, Giovanni
A1 Barnsley, Gregory
A1 Riley, Eleanor M
A1 Khoury, David S
A1 Ferguson, Neil M
A1 Ghani, Azra C
YR 2023
UL http://medrxiv.org/content/early/2023/01/04/2023.01.03.23284131.abstract
AB With the ongoing evolution of the SARS-CoV-2 virus, variant-adapted vaccines are likely to be required. Given the challenges of conducting clinical trials against a background of widespread infection-induced immunity, updated vaccines are likely to be adopted based on immunogenicity data. We extended a modelling framework linking immunity levels and protection and fitted the model to vaccine effectiveness data from England for three vaccines (Oxford/AstraZeneca AZD1222, Pfizer-BioNTech BNT162b2, Moderna mRNA-1273) and two variants (Delta and Omicron) to predict longer-term effectiveness against mild disease, hospitalisation and death. We use these model fits to predict the effectiveness of the Moderna bivalent vaccine (mRNA1273.214) against the Omicron variant using immunogenicity data. Our results suggest sustained protection against hospitalisation and death from the Omicron variant over the first six months following boosting with the monovalent vaccines but a gradual waning to moderate protection after 1 year (median predicted vaccine effectiveness at 1 year in 65+ age group: AZD1222 38.9%, 95% CrI 31.8%-46.8%; BNT162b2 53.3%, 95% CrI 49.1%-56.9%; mRNA-1273 60.0%, 95% CrI 56.0%-63.6%). Furthermore, we predict almost complete loss of protection against mild disease over this period (mean predicted effectiveness at 1 year 7.8% for AZD1222, 13.2% for BNT162b2 and 16.7% for mRNA-1273). Switching to a second booster with the bivalent mRNA1273.214 vaccine against Omicron BA.1/2 is predicted to prevent nearly twice as many hospitalisations and deaths over a 1-year period compared to administering a second booster with the monovalent mRNA1273 vaccine. Ongoing production and administration of variant-specific vaccines are therefore likely to play an important role in protecting against severe outcomes from the ongoing circulation of SARS-CoV-2.Competing Interest StatementACG has participated as a non renumerated member of a scientific advisory board for Moderna, has received consultancy funding from GSK for educational activities related to COVID 19 vaccination and is a member of the CEPI scientific advisory board and Gavi Vaccine Investment Strategy steering committee. She has received grant funding from Gavi for COVID 19 related work. ABH, PW and ACG have previously received consultancy payments from WHO for COVID 19 related work. ABH provides COVID 19 modelling advice to the New South Wales Ministry of Health, Australia. ABH was previously engaged by Pfizer Inc to advise on modelling RSV vaccination strategies for which she received no financial compensation. EMR is a non remunerated member of the UK Vaccines Network, the UKRI COVID 19 taskforce and the British Society for Immunology Covid 19 taskforce.Funding StatementThis work was supported by a grant from WHO. ABH acknowledges support from an Australian National Health and Medical Research Council Investigator Grant and Imperial College Research Fellowship. PW is supported by an Imperial College Research Fellowship. OJW is supported by a Schmidt Science Fellowship in partnership with the Rhodes Trust. GC and ACG acknowledge support from The Wellcome Trust. ABH, PD, PW, GC, GB, SLW, NMF and ACG acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), funded by the UK Medical Research Council (MRC) and part of the EDCTP2 programme supported by the European Union. This work was additionally supported by the NIHR Health Protection Unit for Modelling and Health Economics (NMF: [NIHR200908]); and philanthropic funding from Community Jameel (PD, NMF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used estimates of vaccine effectiveness from England. These are available in references 20 and 21. The study additionally used published data on immunogenicity from reference 12. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in the fitting were extracted from the cited papers and are provided along with all code for the paper on the Github link. https://github.com/mrc-ide/covid_efficacy